Gilead Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission on October 30, 2026, reporting condensed consolidated financial results for the three and nine months ended September 30, 2026.

Key Highlights

  • Q3 2026 product sales: $8,289 million, up from $7,345 million in Q3 2025, according to the filing.
  • Q3 2026 total revenues: $8,300 million, compared to $7,769 million in Q3 2025.
  • Nine-month product sales: $22,862 million for the nine months ended September 30, 2026, versus $21,013 million for the same period in 2025.
  • Acquired in-process R&D expenses: $11,307 million for the nine months ended September 30, 2026, compared to $485 million for the same period in 2025.
  • Total assets: $51,408 million as of September 30, 2026, down from $59,023 million as of December 31, 2025.
  • Retained earnings: $3,107 million as of September 30, 2026, down from $13,730 million as of December 31, 2025.
  • Shares outstanding: 1,240,338,614 shares of common stock as of October 23, 2026.

Gilead Sciences Financial Position and Results for the Nine Months Ended September 30, 2026

According to the filing, Gilead Sciences (NASDAQ:GILD) reported product sales of $8,289 million for the three months ended September 30, 2026, an increase from $7,345 million in the comparable prior-year quarter. Total revenues for Q3 2026 reached $8,300 million, with royalty, contract and other revenues of $11 million, compared to $424 million in Q3 2025. For the nine months ended September 30, 2026, total revenues were $23,063 million versus $21,518 million for the same period in 2025.

On the cost side, the filing disclosed that acquired in-process research and development expenses for the nine months ended September 30, 2026 totaled $11,307 million, a significant increase from $485 million in the same period of 2025. In-process research and development impairments for the nine-month period were $1,750 million, compared to $190 million in the prior-year period. Research and development expenses for the nine months ended September 30, 2026 were $4,744 million, up from $4,215 million. Selling, general and administrative expenses were $5,013 million for the nine-month period, versus $3,980 million in 2025.

The balance sheet as of September 30, 2026 showed total assets of $51,408 million, down from $59,023 million at December 31, 2025. The filing reported cash and cash equivalents of $6,437 million, compared to $7,564 million at year-end 2025. Long-term debt, net stood at $23,815 million as of September 30, 2026, up from $22,129 million at December 31, 2025. Retained earnings declined to $3,107 million from $13,730 million over the same period. Total stockholders' equity was $12,955 million as of September 30, 2026, compared to $22,618 million at December 31, 2025. The filing notes it contains forward-looking statements that are subject to the company's cautionary language and identified risk factors.

What Was Disclosed

Gilead Sciences filed a Form 10-Q for the quarter ended September 30, 2026, disclosing condensed consolidated balance sheets, statements of operations, and related financial data, including a substantial increase in acquired in-process R&D expenses and a decline in total assets and retained earnings compared to year-end 2025.